Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Micrometastasis Breast Cancer: early-phase trial registry

1 of 1 indexed Micrometastasis Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Micrometastasis Breast Cancer: 1 US clinical trial tracked, 1 recruiting.

Micrometastasis Breast Cancer is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 1 of these trials.

Enrollment posture brief

Registry condition micrometastasis-breast-cancer

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Micrometastasis Breast C (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Micrometastasis Breast Cancer

Micrometastasis Breast Cancer lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Micrometastasis Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Micrometastasis Breast Cancer is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Micrometastasis Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Adjuvant Endocrine Therapy Drug
1 trials
Pertuzumab+TRASTUZUMAB Combination
1 trials

US sites by state

Facility locations filed on Micrometastasis Breast Cancer trials. A trial with sites in several states counts in each.

New York 1 trials
New Hampshire 1 trials
Maine 1 trials
Massachusetts 1 trials
Indiana 1 trials
Illinois 1 trials
Georgia 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Micrometastasis Breast Cancer page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Micrometastasis Breast Cancer condition card totals 1 registered trials; most-linked intervention Adjuvant Endocrine Therapy; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.